Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
2 other identifiers
observational
8,000
1 country
73
Brief Summary
This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group. Patients will be included in this study from the moment of completion of the follow-up of the studies of origin and will be followed for approximately 30 years
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Longer than P75 for all trials
73 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 29, 2017
CompletedFirst Posted
Study publicly available on registry
January 4, 2018
CompletedStudy Start
First participant enrolled
January 18, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2047
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2048
May 14, 2025
May 1, 2025
29 years
December 29, 2017
May 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Event Free Survival (EvFS) in neoadjuvant studies.
The EvFS, is defined as the time from the randomization of the patients in the studies of origin, to the date of one of the following events: * Disease progression during neoadjuvant treatment. * Disease relapse (local, regional or distant) after curative surgery. * Second primary tumors * Death due to any cause.
Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
Disease Free Survival (DFS) in adjuvant studies.
DFS is defined as the time from the date of randomization of patients in the studies of origin, to the date of one of the following events: * Disease relapse (local, regional or distant) after curative surgery. * Second primary tumors * Death due to any cause.
Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
Secondary Outcomes (1)
Overall Survival (OS).
Throughout the whole follow up. Up to 30 years from the beginning of the Study approximately.
Eligibility Criteria
Patients with invasive breast cancer (early stages) included in neoadjuvant and adjuvant clinical trials with GEICAM's participation.
You may qualify if:
- Patients included in neoadjuvant and adjuvant clinical trials with GEICAM's participation. If any of these patients had taken part or is participating in another clinical trial, she/he is eligible for this trial and her/his information will also be collected.
- Patients whose death or contact loss has not been previously collected in the databases of the original studies.
You may not qualify if:
- Patient who were not included in the analyses of the original studies due to non-compliance of the eligibility criteria or the original study informed consent withdrawal.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (73)
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain
Hospital San Agustín Avilés
Avilés, Principality of Asturias, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Centro Oncológico de Galicia
A Coruña, Spain
Complejo Hospitalario A Coruña
A Coruña, Spain
Complejo Hospitalario Universitario de Albacete
Albacete, Spain
Hospital General Universitario de Alicante
Alicante, Spain
Hospital General Universitario de Elche
Alicante, Spain
Hospital General Universitario de Elda
Alicante, Spain
Hospital Virgen De Los Lirios
Alicante, Spain
Hospital Infanta Cristina
Badajoz, Spain
Hospital Universitari Germans Trias i Pujol
Badalona, Spain
Consorci Sanitari de Terrassa
Barcelona, Spain
Hospital Clinic i Provincial
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital del Mar
Barcelona, Spain
Hospital Universitario Mutua Terrassa
Barcelona, Spain
Instituto Catalán Oncología Barcelona Hospital Duran I Reynalds
Barcelona, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Hospital Universitario de Burgos
Burgos, Spain
Complejo Especialidades de Jerez de la Frontera
Cadiz, Spain
Hospital Universitario Puerta del Mar
Cadiz, Spain
Complejo Hospitalario de Castellón
Castelló, Spain
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Virgen De La Luz
Cuenca, Spain
Hospital Universitario de Cruces
Donostia / San Sebastian, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Spain
Onkologikoa
Donostia / San Sebastian, Spain
Instituto Catalán de Oncología Gerona Hospital Dr. Josep Trueta
Girona, Spain
Hospital Universitario San Cecilio
Granada, Spain
Hospital Universitario Virgen De Las Nieves
Granada, Spain
Hospital Universitario de Guadalajara
Guadalajara, Spain
Complejo Hospitalario de Especialidades Juan Ramón Jiménez
Huelva, Spain
Complejo Hospitalario de Jaén
Jaén, Spain
Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín
Las Palmas de Gran Canaria, Spain
Hospital de León
León, Spain
Hospital Universitario Lucus Augusti
Lugo, Spain
Hopsital Clínico San Carlos
Madrid, Spain
Hospital de Mostoles
Madrid, Spain
Hospital general Universitario Gregorio Marañón
Madrid, Spain
Hospital Madrid Montepricipe
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Fuenlabrada
Madrid, Spain
Hospital Universitario Fundación Alcorcón
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario La Princesa
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Universitario Severo Ochoa
Madrid, Spain
MD Anderson Cancer Center
Madrid, Spain
ALTHAIA Xarxa Asistencial Universitària Manresa
Manresa, Spain
Hospital Regional de Málaga Carlos Haya
Málaga, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
Hospital General Universitario José María Morales Meseguer
Murcia, Spain
Hospital santa María Naí
Ourense, Spain
Complejo Hospitalario de Palencia
Palencia, Spain
Hospital Álvaro Cunqueiro
Pontevedra, Spain
Corporación Sanitaria Parc Taulí
Sabadell, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Hospital Nuestra Señora De La Candelaria
Santa Cruz de Tenerife, Spain
Hospital Universitario de Valme
Seville, Spain
Hospital Universitario Sant Joan De Reus
Tarragona, Spain
Hospital Virgen de la Salud
Toledo, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Spain
Hospital Arnau Vilanova
Valencia, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital de Sagunto
Valencia, Spain
Hospital General Universitario de Valencia
Valencia, Spain
Hospital Universitari i Politécnic La Fe
Valencia, Spain
Hospital Universitario Dr. Peset Aleixandre
Valencia, Spain
Hospital de Txagorritxu
Vitoria-Gasteiz, Spain
Hospital Clínico Universitario de Zaragoza Lozano Blesa
Zaragoza, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Related Links
Study Officials
- STUDY DIRECTOR
Study Director
Complejo Hospitalario de Especialidades Virgen de la Victoria
- STUDY DIRECTOR
Study Director
Hospital General Universitario Gregorio Marañón
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2017
First Posted
January 4, 2018
Study Start
January 18, 2018
Primary Completion (Estimated)
January 1, 2047
Study Completion (Estimated)
January 1, 2048
Last Updated
May 14, 2025
Record last verified: 2025-05